Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype

NCT05731128 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05731128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05731128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 12, 2023
Completion date
February 22, 2027
Enrollment
68 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

colitis ulcerative